Background: About 5% of pancreatic ductal adenocarcinomas are inherited due to a deleterious germline mutation detected in 20% or fewer families. Pancreatic screening in high-risk individuals is proposed to allow early surgical treatment of (pre)malignant lesions. The outcomes of pancreatic surgery in high-risk individuals have never been correctly explored. Objectives: To evaluate surgical appropriateness and search for associated factors in high-risk individuals. Methods: A patient-level meta-analysis was performed including studies published since 1999. Individual classification distinguished the highest risk imaging abnormality into low-risk or high-risk abnormality, and the highest pathological degree of malignancy of lesions into no/low malignant potential or potentially/frankly malignant. Surgical appropriateness was considered when potentially/frankly malignant lesions were resected. Results: Thirteen out of 24 studies were selected, which reported 90 high-risk individuals operated on. Low-risk/high-risk abnormalities were preoperatively detected in 46.7%/53.3% of operated high-risk individuals, respectively. Surgical appropriateness was consistent in 38 (42.2%) high-risk individuals, including 20 pancreatic ductal adenocarcinomas (22.2%). Identification of high-risk abnormalities was strongly associated with surgical appropriateness at multivariate analysis (P ¼ 0.001). We proposed a score and nomogram predictive of surgical appropriateness, including high-risk abnormalities, age and existence of deleterious germline mutation. Conclusion: Overall, 42.2% of high-risk individuals underwent appropriate surgery. The proposed score might help selecting the best candidates among high-risk individuals for pancreatic resection.
Introduction
The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing and is predicted to be the second leading cause of cancer-related death by 2030. 1 Inherited forms of the disease represent 5% of cases. 2, 3 A putative causal germline mutation can be identified in less than 20% of families. 4, 5 In contrast, no deleterious germline mutation has been identified in most families with multiple PDACs (80-85%). Such familial aggregation of PDAC is called familial pancreatic cancer (FPC) 2, 5 and is defined as the occurrence of PDAC in two or more first-degree relatives (FDRs), or in three or more relatives whatever the degree. 2, 5, 6 Currently, despite expert consensus have been proposed, there are no validated guidelines for screening programmes. Screening usually relies on yearly magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) but its precise value has not been clearly assessed, and the role of computed tomography (CT) must still be evaluated. 7 The aim of screening in high-risk individuals (HRIs) is to identify those who present morphological abnormalities suggesting the development of PDAC. Ideally, the goal is to propose early surgical treatment of premalignant lesions (such as pancreatic intraepithelial neoplasia (PanIN) or intraductal papillary mucinous neoplasms (IPMNs) with high-grade dysplasia) 8 or even early stage invasive PDAC. Surgical resection of these (pre)malignant lesions could potentially cure up to 80% of patients. 7, 9, 10 However, the optimal time to perform surgery in HRIs, i.e. neither too early (low grade lesions) nor too late (advanced PDAC), must still be determined and the rate of morbidity-mortality of pancreatic resection remains significant. [10] [11] [12] [13] Moreover, the outcomes of pancreatic surgery in HRIs have never been correctly explored, in particular due to the limited size of these studies. We aimed to perform a patient-level metaanalysis of all observational studies reporting on the surgical management of HRIs, with the objective to evaluate the appropriateness of prophylactic pancreatic resection in HRIs who were followed by screening and to develop a nomogram to predict surgical appropriateness.
Patients and methods

Selection of studies
We performed a patient-level meta-analysis of all series published between 1999 and 2017 on the screening of PDAC in HRIs and treatment of detected (pre)malignant lesions. Selected studies were identified by a search of the PubMed database with no language restriction. The keywords used were 'familial pancreatic carcinoma', 'hereditary pancreatic cancer', 'high risk individuals' and 'screening'. Two independent searches were performed. Thirteen out of 24 identified studies were selected because they fulfilled the following criteria ( Figure 1 ):
. Studies including HRIs defined by the following strict criteria: (a) patients affected by a familial germline mutation of the LKB1/STK11 gene whatever the number of FDRs with PDAC or of another gene (i.e. BRCA1, BRCA2, PALB2, CDKN2A, TP53, PRSS1, ATM and mismatch repair genes) and one or more FDR with PDAC; or (b) patients with FPC defined by two or more FDRs with PDAC or three or more relatives whatever the degree. 5, 7 . Studies reporting individual data on pancreatic surgery: indication according to morphological description of pancreatic abnormalities detected during screening, type of surgery and final pathological analysis of the resected specimen.
The 11 studies that did not fulfill these criteria are listed in Supplementary Table 1 . The studies that included duplicate data from the same patients published elsewhere were excluded. In this case, only the most recent study was retained.
Data collection
We excluded individuals who did not fulfill the abovementioned criteria, such as those with only one FDR affected with PDAC. 6, 15, 16 The following data were obtained for all included subjects: gender, known germline mutation or FPC, age at surgery, abnormalities identified at screening, type of resection, pathological analysis of surgical specimen, duration of postoperative follow-up and survival status of patients when available.
Pancreatic abnormalities identified during followup were reviewed at the individual level and were classified as:
. Low-risk abnormalities (LRAs): cyst less than 30 mm, main pancreatic duct size less than 5 mm and no mural nodule. . High-risk abnormalities (HRAs): presence of 'worrisome features' (i.e. cyst !30 mm, enhancing mural nodule <5 mm, thickened/enhancing cyst walls, main pancreatic duct diameter 5-9 mm, abrupt change in the caliber of the pancreatic duct, cyst growth rate !5 mm/2 years and/or lymph nodes) or presence of 'high-risk stigmata of malignancy' (biliary obstruction, enhancing mural nodules !5 mm and/or main pancreatic duct diameter !10 mm) by extrapolation of international consensus for IPMN 17, 18 and the presence of a solid mass whatever the size and/or sample (cytology or biopsy) suspicious or positive for malignancy.
If a patient had multiple abnormalities, only that with the highest risk of malignancy was considered.
Individual pathological data of resected specimens were reviewed and classified into two categories depending on the lesion with highest malignant potential:
. Criteria used were based on the current international consensus guidelines. 8 PDAC was classified following the 8th American Joint Commission on Cancer classification. 19 Surgical appropriateness was defined as the presence of potentially/frankly malignant lesions on the final pathological examination of resected specimens. Conversely, surgical non-appropriateness was defined as the presence of only non-malignant lesions.
Statistical analysis
The primary judgement criterion was the rate of surgical appropriateness in HRIs who underwent pancreatic surgical resection for abnormal imaging findings diagnosed during screening.
Qualitative variables were described as frequencies (percentages) and compared with the chi-squared test. Quantitative variables were described as medians (25-75 interquartile) and compared with the MannWhitney test. The performances (sensitivity, specificity, positive and negative predictive values) of morphological criteria for the diagnosis of surgical appropriateness were calculated.
To explore the factors associated with surgical appropriateness, we performed univariate logistic regression analysis of all relevant variables. Then all clinically relevant variables with P 0.20 on univariate analysis were entered into a multivariate logistic regression model. The variables from multivariate analysis were used to create a nomogram to estimate the probability of surgical appropriateness. A predictive model was constructed and weighted with b-coefficient estimations from the multivariate model. An individual-level predictive score was built with nomogram total points.
Overall survival was defined as the time between the date of pancreatic surgery and death from any cause,
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HRI who underwent pancreatic surgery, n = 90 or the date of the last news. Living patients were censored at the date of the last follow-up. Median overall survival was calculated using the Kaplan-Meier method. Survival curves were compared using the log rank test. All tests were performed with SPSS (version 20.0, IBM) and Prism (version 6, Graphpad) softwares. A P value of less than 0.05 was considered to be statistically significant. The PRISMA checklist is given in Supplementary Table 2 .
Results
Study characteristics
All 13 studies included were prospective and six were multicentre 6, [14] [15] [16] [20] [21] [22] [23] [24] [25] [26] [27] [28] (Table 1 ). The 13 studies included 1747 screened HRIs. The proportion of screened HRIs with morphological abnormalities was only reported in eight studies (511/1150, 44.4%). The median number per study of screened HRIs was 95 (44-216) and of operated HRIs was five (three to seven).
Screening was performed by different imaging modalities, but mainly EUS and MRI. MRI was first reported for screening in 2009 and became routine after 2012. Four series did not describe the MRI protocol, [20] [21] [22] 26 one provided a minimum protocol (T2-weighted only), 15 and one reported MRI with secretin injection, 24 although the usefulness of the latter was not assessed. Finally, a few series used an exhaustive MRI protocol with gadolinium injection, 14, 23, 24 and only one included additional diffusion-weighted sequences. 28 The usual interval between imaging examinations was one year. In the case of imaging abnormalities, a CT scan and EUS were usually performed in addition to the initial MRI, and then repeated with shorter (3-6 months) intervals.
Patient characteristics
The 13 included studies evaluated 90 HRIs who were operated on due to abnormal pancreatic imaging findings during screening, with lesions considered to be at risk of (pre)malignancy. There were too few reports on the delay between the beginning of screening and surgery to be analysed. The characteristics of operated HRIs are presented in Table 2 . The median age was 58 (51-66) years and 20 patients (22.2%) were less than 50 years old. The two most frequent morphological abnormalities leading to surgery were cystic lesions with benign features (46.7%) and solid masses (28.9%). Overall, LRAs or HRAs were identified during screening in 46.7% and 53.3% of operated patients, respectively. In patients with HRAs, the detected lesion with the highest theoretical risk was a cystic lesion(s) with worrisome features in 13.3%, highrisk stigmata in 1.1%, or a solid mass in 28.9%. Finally, 10% of patients had positive cytology/biopsy ( Table 2) .
The two most frequent surgical procedures were left pancreatectomy (54.4%) and pancreatico-duodenectomy (25.6%). Twelve patients (13.3%) underwent a total pancreatectomy. No surgery-related deaths were reported. Left pancreatectomy was more frequently performed for LRAs than pancreatico-duodenectomy or total pancreatectomy (57% vs. 31%, P ¼ 0.02). Pathological examination of the resected specimen showed non-malignant lesions in 57.8%, mostly branch duct IPMN or PanIN with low-grade dysplasia. Potentially/frankly malignant lesions were identified in the remaining 42.2%, including 20 (52.6%) with invasive PDAC. Among those 20 PDAC, eight were classified stage I (six stage IA and two stage IB), seven were classified stage II (two stage IIA and five stage IIB) and five were classified stage III. It was generally not determined whether PDAC was identified at the first screening or during follow-up.
Proposal of the Beaujon score and nomogram
Overall, based on the definition proposed above, surgery was found to be appropriate in 38 HRIs or 42.2% of all operated HRIs. The sensitivity, specificity, positive and negative predictive values of the proposed morphological criteria (HRAs vs. LRAs) was 81.6%, 67.3%, 64.6% and 83.3%, respectively.
The factors associated with surgical appropriateness on univariate analysis (Table 3) were the presence of a germline mutation in screened HRIs (vs. FPC, P ¼ 0.011) and HRAs identified during screening (vs. LRAs, P < 0.001). Age greater than 50 years (P ¼ 0.20) tended to be associated with surgical appropriateness. At multivariate analysis, the only factor independently and significantly associated with surgical appropriateness was surgery performed for HRAs (vs. LRAs, hazard ratio (HR) 11.69, 95% confidence interval (CI) 3.71-36.81, P ¼ 0.001).
A nomogram was built that included the three variables entered into multivariate analysis. The Beaujon score was then developed to predict the probability of surgical appropriateness of pancreatic resection in HRIs (Figure 2 ). This score was based on the total number of points obtained from the nomogram, with a minimum of 0 (all three variables negative) corresponding to a probability of surgical appropriateness of approximately 5%, and a maximum of 180 (all three variables positive) corresponding to a probability of surgical appropriateness of 80%. The area under the receiver operating characteristic (ROC) curve of the predictive model was 0.81 (compared with 0.77 when non-weighted variables were used). 
Survival analyses
The duration of follow-up and survival in non-operated HRIs was not reported. 
Discussion
To our knowledge, this is the first study to propose a patient-level meta-analysis to evaluate the controversial question of the 'appropriateness' of pancreatic surgery Beaujon score and nomogram to predict the probability of the appropriateness of prophylactic pancreatic resection in high-risk individuals following screening. First, the points associated with each of the three predictive factors are obtained by vertical translation from the patient's value to the 'points' line. All variables are binary. Next, the points are summed and the corresponding total number is reported on the 'total points' line. A vertical line is then drawn downward from the total points line to obtain the probability of surgical appropriateness. in HRIs who receive pancreatic screening. All the previously published studies limited populations and were mainly descriptive. The present meta-analysis was performed to obtain sufficient statistical power for inferential analysis. Our main result is that 42.2% of HRI surgeries were appropriate while 57.8% of the remaining patients had lesions of no/low malignant potential. In addition, surgery was beneficial in 20% of operated HRIs who underwent resection of potentially/frankly malignant lesions before the development of invasive adenocarcinoma and who did not die from PDAC. These results suggest that selection of HRIs for pancreatic surgery should be optimised. Performing surgical resection before the disease becomes invasive (high-grade dysplasia), or achieving R0 resection at the earliest stage possible in patients with invasive tumours would provide the highest chance of cure. Hence, only HRIs with potentially/frankly malignant lesions should be ideally selected for surgery, while follow-up should be continued in those without. Our study showed that proposing surgery in cases of high-risk dysplasia could increase survival (2-year rate of 100% vs. 55.8% in the case of invasive PDAC). Interestingly, the outcome in this subgroup of patients was highly favourable and similar to that in patients operated for lesions with no/low potential malignancy, with a high chance of cure. Conversely, the survival of HRIs operated with invasive PDAC (median, 35 months) was similar, or slightly better, to that of patients operated on for sporadic PDAC not undergoing any previous screening (25-28 months in one recently published trial). 29 Hence, surgery might have been performed too late in those patients despite screening.
This study was not designed to evaluate the value or benefit of pancreatic screening itself, but to assess surgical appropriateness. The number of HRIs who underwent surgery cannot be compared with those who were screened. First, the delay between the beginning of screening and surgery could not be analysed and postsurgical follow-up was only 29 months, thus the possibility of developing late recurrence or second pancreatic premalignant lesions could not be excluded. Second, the rate of patients with PDAC who did not undergo surgery and the duration of screening in nonoperated HRIs were not reported. Thus this study only provides an image at the time of surgery and does not give information on the natural history of pancreatic (pre)malignant lesions in HRIs.
Our analyses showed that the identification of HRAs at screening was significantly associated with potentially/frankly malignant lesions in the surgical specimen, which is consistent with recent published data. 30 There is a consensus on the morphological description of sporadic IPMN-associated worrisome features and high-risk stigmata of malignancies. 18 PDAC develops from both IPMN and PanIN, the imaging features of the latter have been poorly described, and data on the morphological distinction between low-grade and high-grade PanIN are even more limited. 31 Hence the morphological criteria used to define LRAs and HRAs in our study were voluntarily inspired from criteria for sporadic IPMN, with a relevant prognostic impact on our model.
Although both the sensitivity (81.6%) and negative predictive value (83.3%) of the morphological features of pancreatic lesions were acceptable, the specificity (67.3%) and positive predictive value (64.6%) were insufficient. Thus, it seems inadequate as a single criterion for patient selection because this would result in a high rate of surgery for benign lesions. Other original criteria were identified in our analysis, including the presence of a deleterious germline mutation (vs. FPC setting) and age greater than 50 years, although they did not reach statistical significance probably due to low statistical power. Bartsch et al. 6 reported that pancreatic screening rarely revealed significant and potentially relevant lesions before the age of 50 years, although almost all screening programmes propose to begin screening at age 40-45 years or 10 years less than the youngest age of PDAC in the family. We proposed a nomogram to predict surgical appropriateness at the individual scale. Even if some variables were not independently associated with surgical appropriateness, some of them interacted significantly in the model, justifying the use of three variables in the Beaujon score. The nomogram was accurate, with an area under the ROC curve of 0.81. Finally, while this score could help improve the caseby-case management of patients, it was developed based on data obtained from a meta-analysis and it must be prospectively validated in an independent cohort of HRIs.
The relevance of surgical decision-making in HRIs involves the detection methods used during initial screening and subsequent follow-up. The present meta-analysis reveals wide heterogeneity between studies. 7 For instance, MRI has progressively replaced CT scan and became routine after 2012. EUS and MRI are complementary and their contribution to pancreatic screening is essential as they have increased the detection of abnormal findings in HRIs. 28 Systematic sampling is an invasive tool, not always feasible due to the limited size of pancreatic abnormalities. In our meta-analysis one third of patients (three out of nine) with positive cytology or biopsy did not have potentially/frankly malignant lesions on the resected specimen. In all three patients sampling was performed by fine-needle aspiration. This rate of false positive is unusually high, in comparison with the 2% rate reported in the literature. 32 Explanations are unknown; this might be due to interpretation errors, or subjectivity bias, i.e. overestimation of the grade of dysplasia due to the acknowledgement of the setting of HRI screening. Besides, the sensitivity of malignant cytology was lower in our analysis (66%) in comparison with the usual sensitivity (85%). 32 This might be explained by the fact the patients included in our meta-analysis may have been treated a longer time ago, using techniques of endoscopic sampling and pathological analysis with lower performances. Still, in the case of sample indicating potentially/frankly malignant lesions, it is currently mandatory to propose surgical resection, while explaining to the patient that cytology may have been falsely positive. The future probably lies in molecular biomarkers of pancreatic juices, [33] [34] [35] but detecting biological stigmata of HRAs before the occurrence of invasive carcinoma will be an even more difficult challenge. The sensitivity of circulating tumour cells/DNA plasma detection is still low and has not been assessed for the screening of HRIs.
This study has the limitations associated with its retrospective design. To limit selection bias, we performed a strict selection of articles and a thorough analysis of all individual data, to avoid multiple inclusions of redundant patients already included in previous studies from the same team. Although there was heterogeneity among studies, all data (including morphological, surgical and pathological) were re-analysed using standardised and consensual grading systems to enable pooled analysis. Finally, the number of included HRIs in each study was relatively low, which justified that meta-analysis; but still, it may have induced a lack of statistical power.
In conclusion, this patient-level meta-analysis suggests that surgery was appropriate in 42.2% of HRIs who underwent pancreatic surgery in the literature. Morphological characterisation of lesions was strongly associated with surgical appropriateness, but age (!50 years) and the presence of a deleterious germline mutation could also improve patient selection for surgery. The score and the nomogram we proposed to help in surgical decision require prospective validation in large cohorts with adequate longer-term follow-up.
